

**AZACTAM (aztreonam) 1g Powder for Solution for Injection or Infusion  
(PL 12038/0002)**

Page 1/2

**UK Notification of Product Shortage**

July 2024

Dear Customer,

Bristol-Myers Squibb (BMS) Pharmaceuticals Unlimited Company wish to provide an update on the temporary stock shortage of **AZACTAM (aztreonam) 1g Powder for Solution for Injection or Infusion** in the United Kingdom market that was previously communicated in June 2024. The supply shortage is due to a manufacturing delay. It is not related to a safety or quality issue.

We are anticipating a new limited shipment of the **Azactam (Aztreonam) 1g presentation** in July 2024, however, this will not be sufficient to meet anticipated demand for the 1g presentation.

During this period, we will continue to have a limited supply of **AZACTAM (aztreonam) 2g Powder for Solution for Injection or Infusion**. We request that prescribers continue to prioritise the ordering of the product for patients who have the greatest need.

BMS will provide an update on estimated resupply dates of both the Azactam 1g and 2g presentations by August 2024.

There are no generic aztreonam alternatives available in the United Kingdom. This interruption in supply may require health providers to switch patients to other alternatives. BMS cannot recommend a specific product. Prescribing an alternative product is a clinical decision to be taken by the patient's healthcare professional in consultation with the patient. These alternatives may have a different efficacy and safety profile. For product information on alternatives, you may wish to contact the manufacturers of these products.

BMS recognises the importance of aztreonam to patients and is doing everything we can to minimise the interruption in supply.

**Reporting of suspected adverse reactions**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or [medical.information@bms.com](mailto:medical.information@bms.com).

**Company Contact Point**

If you have any further questions in relation to Azactam, please contact the BMS Medical Information department at 0800 731 1736 or via email at [medical.information@bms.com](mailto:medical.information@bms.com).

Page 2/2

Yours Sincerely,



---

Andrew Holgate (Jul 4, 2024 22:30 GMT+1)

Andrew Holgate, MBBS BSc(Hons) DPM MFPM  
Associate Director, Medical Lead | Immunoscience  
UK & Ireland Bristol Myers Squibb

Job Code: NO-GB-2400166

Date of preparation: July 2024